Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Operations (2016 - 2025)

ImmunityBio (IBRX) has disclosed Cash from Operations for 12 consecutive years, with 70378000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 17.34% to 70378000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 304936000.0 through Dec 2025, up 22.06% year-over-year, with the annual reading at 304936000.0 for FY2025, 22.06% up from the prior year.
  • Cash from Operations for Q4 2025 was 70378000.0 at ImmunityBio, down from 68858000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 60469000.0 in Q1 2021, with the low at 115271000.0 in Q4 2023.
  • Average Cash from Operations over 5 years is 83742850.0, with a median of 82455000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations crashed 96.58% in 2021, then surged 30.28% in 2025.
  • Over 5 years, Cash from Operations stood at 71639000.0 in 2021, then fell by 26.64% to 90727000.0 in 2022, then dropped by 27.05% to 115271000.0 in 2023, then rose by 26.14% to 85144000.0 in 2024, then increased by 17.34% to 70378000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 70378000.0, 68858000.0, and 79800000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.